The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Oncologists rely heavily on hormone and HER-2 status to guide treatment recommendations for women with breast cancer. If the results of these important tests are incorrect up to 20% of the time, we may be suboptimally treating many breast cancer patients.
Medical oncologists have "maxed out" on chemo combinations in lung cancer. It is clear that biologic agents need to be incorporated into our treatment regimens in order to move forward. Erbitux is safer and can be used in a broader population of lung cancer patients than Avastin.
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
There is no reason to believe Dacogen is inferior to Vidaza. In some studies, Dacogen seems to produce a deeper quality of response, and may also prove more beneficial in AML.
Revlimid benefits are often over-stated in non-5Q minus MDS. The cost is a hurdle for many patients with poor prescription plans. Vidaza and Dacogen seem superior in my experience for higher risk patients.
This article reports on Varian's answer to Tomotherapy which has been gaining some market share in the Radiation Oncology linear accelerator arena. Tomotherapy has a good product but requires a shift in treatment planning technique and complete replacement of hardware. There have been reports about...
The current understanding of heart risks from chemotherapy does not stop oncologists from giving chemotherapy for early breast cancer in those who need it.
Better drugs for preventing relapse are certainly welcome, when they are developed.